Analyst upgrades typically lead to a positive short-term reaction in the stock market as they suggest improved fundamentals or prospects for the company. The substantial increase in the price target from $1 to $5 by a major financial institution like Citigroup is a strong vote of confidence in Mersana Therapeutics, which could lead to increased investor interest and a potential rise in the stock price.